tiprankstipranks

Analyst Profile

Followed by 809 followers
.
John Newman

John Newman

Canaccord Genuity
Wall Street Analyst
#6,350 out of 7,962 Wall Street Analysts
#17,884 out of 22,231 experts

Success Rate

35%
124 out of 358 transactions made a profit

Average Return

-1.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying John Newman's trades since 2009 and holding each position for 1 Year would result in 34.64% of your transactions generating a profit, with an average return of -1.8% per rating.

Stock Rating Distribution

1KRatings
88.11% Buy
10.85% Hold
1.04% Sell
Distribution of John Newman's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market
CanadaCanadian Market

Best Rating

Stock:
Seres Therapeutics Inc.
(MCRB)
Rating:Buy
Date:Nov 05, 2019 - Nov 05, 2020
Return:+767.40%
The most profitable rating made by John Newman

John Newman's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Brunswick
Jun 10, 2009
Sell
Reiterated
1Ratings
0.00%
VPHM
Viropharma
Sep 28, 2009
Buy
Upgraded
1Ratings
0.00%
SLXP
Salix
Mar 10, 2010
Buy
Reiterated
1Ratings
0.00%
MannKind
Mar 15, 2010
Sell
Downgraded
$5.00
(62.87% Upside)
2Ratings
0.00%
CADX
Cadence Pharma
Apr 16, 2010
Sell
Downgraded
1Ratings
0.00%
QCOR
Questcor
Jun 10, 2010
Buy
Reiterated
1Ratings
0.00%
SVNTQ
Savient Pharmaceuticals
Sep 16, 2010
Hold
Downgraded
4Ratings
0.00%
Endo International
Sep 29, 2010
Buy
Upgraded
$40.00
(30931.81% Upside)
3Ratings
0.00%
Biogen
Dec 20, 2011
Buy
Assigned
$127.00
(-35.79% Downside)
45Ratings
0.00%
Apollo Endosurgery
Apr 16, 2014
Buy
Initiated
$17.00
(230.10% Upside)
2Ratings
0.00%
List of latest recommendations made by John Newman. Click to expand and see John Newman's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >